Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Outlook Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$55.53M. For fiscal 2025 it was -$66.94M. The highest annual figure on record is -$26.59M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$66.94M | – |
| FY2024 | Sep 30, 2024 | -$71.59M | – |
| FY2023 | Sep 30, 2023 | -$53.08M | – |
| FY2022 | Sep 30, 2022 | -$62.87M | – |
| FY2021 | Sep 30, 2021 | -$51.46M | – |
| FY2020 | Sep 30, 2020 | -$36.29M | – |
| FY2019 | Sep 30, 2019 | -$32.94M | – |
| FY2018 | Sep 30, 2018 | -$26.59M | – |
| FY2017 | Sep 30, 2017 | -$33.19M | – |
| FY2016 | Sep 30, 2016 | -$48.95M | – |
| FY2015 | Sep 30, 2015 | -$44.74M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$10.80M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$14.00M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$13.45M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$17.28M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$15.72M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$12.36M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$21.58M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$22.85M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$19.53M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$18.91M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$10.29M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$12.45M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$18.13M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$6.83M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$15.68M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$13.94M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$13.10M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$13.38M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$14.11M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$9.93M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$11.83M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$6.70M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$8.01M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$11.80M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$4.81M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$6.89M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$9.43M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$11.59M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$6.40M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$6.12M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$2.50M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.24M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$6.66M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$7.16M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$17.13M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$9.35M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$21.43M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$2.36M | – |
See a number that looks wrong?